An interventional study of Symptom-Targeted Approach to Rehabilitation for Concussion in Mild Traumatic Brain Injury (mTBI), sponsored by Henry M. Jackson Foundation for the Advancement of Military Medicine. Recruiting at 2 sites in United States. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2026-01-08.
Sponsored by Henry M. Jackson Foundation for the Advancement of Military Medicine · Not applicable, Interventional, and Treatment
How we know · 2 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 420 studies in Brain Concussion with a site in United States — 102 open to participants now, 123 under way, 5 of them phase 3. Brain Concussion · United States.
Among the 420 studies in Brain Concussion with a site in United States, this one is the 51st largest by planned enrollment of the 323 interventional ones that give a count, is one of 27 that started in 2025, is one of 265 with no phase, reaches primary completion later than 35 of the 122 other live ones, and was the 372nd registered.
641 studies on the registry are indexed under Brain Concussion; 167 are open to participants now.
Browse Brain Concussion studies →102 of the 420 studies in Brain Concussion with a site in United States are open now. Recruiting first, the newest first:
Johns Hopkins University · Sites in United States
Ages 18–55
HealthPartners Institute · Sites in United States
Ages 18–65
University of Michigan · Sites in United States
Ages 18+
Perception Dynamics Institute · Sites in United States
Ages 18–60
University of Colorado, Denver · Sites in United States
Ages 18+ · Men only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 114 Brain Concussion studies recruiting now, 34 (30%) set no upper age limit and 73 (64%) stop at 75 or younger; 24 take children under 18; 38 take healthy volunteers.
This study: 18 Years to 64 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
420 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 21 · Phase 2 29 · Phase 3 9 · Phase 4 5
First in 1998; this study’s year is marked. 27 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 222 is above the median of 63 across 449 interventional studies indexed under Brain Concussion.
Median enrollment 60 across the 323 interventional studies, 147 across the 96 observational. Of the 259 that completed or were terminated, 68 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
59 of 420 have an industry lead sponsor. The 10 most frequent:
Henry M. Jackson Foundation for the Advancement of Military Medicine is the lead sponsor of 87 studies on the registry; 18 are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 2 (29%) have results posted.
Henry M. Jackson Foundation for the Advancement of Military Medicine has 8 studies filed under Brain Concussion — fewer than ten, so there is no comparison to draw.
50 of the studies in Brain Concussion with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04867317Phase 3VA Office of Research and DevelopmentGrowth Hormone Replacement Therapy in Veterans With Mild Traumatic Brain Injury (mTBI) and Adult Growth Hormone Deficiency (AGHD) | 2027-02-28 |
| NCT05320822University of North Carolina, Chapel HillA Pragmatic Rehabilitation Intervention: The Active Rehab Study | 2026-11-28 |
| NCT06109909VA Office of Research and DevelopmentPilot Study of Neurofeedback for Photosensitivity in Mild Traumatic Brain Injury | 2026-11-30 |
| NCT02670161Endeavor HealthQuality Improvement and Practice Based Research in Neurology Using the EMR | 2026-12 |
| NCT04708613David Okonkwo, MD, PhDUniversity of Pittsburgh Brain Health Initiative | 2026-12 |
Add all 50 to your calendar (.ics) → With an account.
Among the 420 studies in Brain Concussion with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Purpose: Investigators propose a three-arm RCT across two military treatment facilities:1) in-person STAR-C, 2) telehealth STAR-C, and 3) no treatment control. Outcomes will be assessed immediately and at one- and three-months post treatment.
Hypothesis/Objectives: STAR-C, delivered in-person and via telehealth, will be effective in decreasing everyday cognitive complaints among patients with a history of mTBI. Effectiveness will be moderated by patient characteristics. Stakeholder feedback will yield a process map for broad implementation of STAR-C in varied clinical environments.
Specific Aim 1 (primary for RCT): To evaluate effectiveness of STAR-C.
Hypothesis 1a: In-Person STAR-C will lead to a greater decrease in everyday cognitive complaints (C4) compared to wait-list control.
Hypothesis 1b: Tele STAR-C will lead to a greater decrease in everyday cognitive complaints (C4) compared to wait-list control.
Specific Aim 2 (secondary): To evaluate maintenance of treatment effects using a practice based evidence approach.
Question 2a: What proportion of in-person STAR-C treatment effects (C4 and GAS) will be maintained at the 3-month follow-up?
Question 2b: What proportion of telehealth STAR-C treatment effects (C4 and GAS) will be maintained at the 3-month follow-up?
Specific Aim 3 (exploratory): To explore factors associated with heterogeneity in treatment response.
Question 3a: What factors prevented participants from achieving a ≥2-point improvement on the C4?
Question 3b: What factors prevented participants from maintaining ≥2-point improvement on the C4?
Question 3c: What factors prevented participants from achieving ≥2 out of 3 targets using GAS?
Question 3d: What factors contributed to participants maintaining or exceeding targets (GAS) at the 3-month follow-up?
Specific Aim 4 (implementation): Use stakeholder input (to include clinicians, administrators, and patients) from capacity assessment and after-action review to generate an implementation package for clinics interested in STAR-C.
Question 4: For what proportion of patients will clinicians rate STAR-C as acceptable, appropriate, and feasible (AIM/IAM/FIM)?
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Individuals randomized to this arm will go for 4 weeks without treatment. During this time, participants will be asked to remain stable on treatments that they are already receiving for their concussive symptoms; that is and should not start a new treatment or change their medication. At the end of the 4-week wait, participant's will be asked about any changes to treatments that they have received during this time, and participants will be asked to complete questionnaires. This visit can be complete in person or remotely. Participants will be randomized into the in-person or telemedicine group.
Behavioral: Symptom-Targeted Approach to Rehabilitation for Concussion
Individuals assigned to this treatment will receive in-person individual cognitive rehabilitation treatment conducted by credentialed speech or occupational therapists. Participants will complete up to three sessions per week (approximately 50 minutes each) for up to nine sessions plus one wrap up session. The treatment will include a focus on compensatory strategies and weekly homework assignments. Participants will work on personalized targets and assignments. The treatment will end with one wrap up session where participants will put together a plan for maintenance of what they have learned with their therapist's help.
Behavioral: Symptom-Targeted Approach to Rehabilitation for Concussion
Individuals assigned to this treatment will receive individual cognitive rehabilitation treatment conducted by credentialed speech or occupational therapists via a telemedicine format. Participants will complete up to three sessions per week (approximately 50 minutes each) for up to nine sessions plus one wrap up session. The treatment will include a focus on compensatory strategies and weekly homework assignments. Participants will work on personalized targets and assignments. The treatment will end with one wrap up session where participants will put together a plan for maintenance of what they have learned with their therapist's help.
Behavioral: Symptom-Targeted Approach to Rehabilitation for Concussion
This study is looking at a shortened version of a therapist-direct cognitive rehabilitation intervention, known as STAR-C. STAR-C is focused on strategy use, and for strategy use to become a habit the person must have the opportunity for high-dose spaced practice. Thus, in STAR-C each session includes opportunities for repeated practice and participants schedule practice times between sessions. Sometimes a new strategy requires learning new facts, in which case the clinician chooses ingredients such as self-quizzing or comparing and contrasting outcomes, which are effective for learning new facts and concepts.
Common Concussive Cognitive Complaints (C4)
On the C4, patients are asked to "identify challenges that are new since your injury and affect your everyday functioning, so we can focus therapy on what is most important to you." For each question, the patient is asked to choose the number that shows how often this has caused problems for them in everyday life in the past two weeks. Responses are on a scale from 1 (not at all) to 5 (all the time). The reliability and validity of the C4 are acceptable (internal consistency of domains: 0.465 to 0.797; 4-week test-retest reliability of domains: 0.628 to 0.832; convergent validity with MMPI-3 Cognitive Complaints and Inefficiency scales and discriminant validity with MMPI-3 Activation and Eating Concerns scales).
Time frame: From baseline to 3 months post treatment
Goal Attainment Scaling (GAS)
As described above in the Summary of ongoing relevant clinical trials, in each session, the patient and therapist collaborate to identify a desired outcome for the patient's target and then scale it using a 5-point rating system. The patient's current state relative to the target is assigned a 0 on the scale, achievement of the desired target is +2, partial achievement is +1, and achievement beyond expectations is +3. Success is defined as a GAS score of 2 or 3.
Time frame: From treatment week 1 to 3 months post treatment
Evaluate maintenance of treatment effects
Question 2a: At the 3-month follow-up, determine the proportion of in-person STAR-C participants with ≥2 points C4 improvement post treatment maintained their improvement using contingency table or McNemar test. Question 2b: At the 3-month follow-up, determine the proportion of telehealth STAR-C participants with ≥2 points C4 improvement post treatment maintained their improvement using contingency table or McNemar test. Question 2c: At the 1-month and 3-month follow-ups, describe rates of maintaining ≥2 points C4 improvement for the in-person and telehealth STAR-C groups.
Time frame: From baseline to 3 months post treatment
To explore factors associated with heterogeneity in treatment response. Statistical approach will be determined after potential factors are evaluated for differences between the RCT arms
Question 3a: Determine what factors, if any, that may have prevented participants from achieving a ≥2 point C4 improvement at the end of treatment. Question 3b: Determine what factors, if any, that may have prevented participants from maintaining at ≥2 point C4 improvement at the 3-month follow-up. Question 3c: Determine what factors, if any, that may have prevented participants from achieving ≥2 out of 3 targets using GAS. Question 3d: Determine what factors, if any, that may have contributed to participants maintaining or exceeding targets (GAS) at the 3-month follow-up.
Time frame: From baseline to 3 months post treatment
Plan to share: Yes — Common Concussive Cognitive Complaints (C4); Goal Attainment Scaling (GAS); Audio recordings; Patient Characterization Measures (headache, sleep problems, dizziness, musculoskeletal injury and pain, medications, and use of commercial brain games); Neurobehavioral Symptom Inventory (NSI); Key Behaviors Change Inventory (KBCI); Post-traumatic Stress Disorder Checklist for DSM-5 (PCL-5); Patient Health Questionnaire (PHQ-9); Veterans RAND 36 Item Health Survey (VR-36); Epworth Sleepiness Scale (ESS); Feasibility of Intervention Measure (FIM)/Intervention Appropriateness Measure (IAM)/Acceptability of Intervention Measure (AIM); Self Efficacy for Symptom Management (SESx); NIH Toolbox - cognition; Memory Complaints Inventory (MCI); Inventory of Problems (IOP)
Supporting information: Clinical study report
Time frame: Beginning after data collection ends with no end date
Access criteria: Brain Injury Rehabilitation Service at Brooke Army Medical Center, Brain Injury Rehabilitation Service at Desmond T. Doss Health Clinic and McMaster University will be sent de-identified data that will be transmitted using DoD SAFE, which is a DoD endorsed platform for transferring data securely; De-identified data will be uploaded directly to Federal Interagency Traumatic Brain Injury Research (FITBIR) database;
Started Sep 2025 (actual). Primary completion is estimated for Dec 2026, 15 months after the start.
Of 249 non-industry interventional studies with no phase under Brain Concussion, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 47. This study's planned 15 months is below that.
Counting every sponsor, half of 265 studies reached it within 28 months; a quarter within 19 and three quarters within 47.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Henry M. Jackson Foundation for the Advancement of Military Medicine